Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

Lloret A, Beal MF.

Neurochem Res. 2019 May 7. doi: 10.1007/s11064-019-02809-1. [Epub ahead of print]


Nicotinamide riboside attenuates alcohol induced liver injuries via activation of SirT1/PGC-1α/mitochondrial biosynthesis pathway.

Wang S, Wan T, Ye M, Qiu Y, Pei L, Jiang R, Pang N, Huang Y, Liang B, Ling W, Lin X, Zhang Z, Yang L.

Redox Biol. 2018 Jul;17:89-98. doi: 10.1016/j.redox.2018.04.006. Epub 2018 Apr 5.


Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models.

Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, Wang J, Sastre M, Ono K, Sauve AA, Pasinetti GM.

Neurobiol Aging. 2013 Jun;34(6):1581-8. doi: 10.1016/j.neurobiolaging.2012.12.005. Epub 2013 Jan 9.


Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models.

Naia L, Rosenstock TR, Oliveira AM, Oliveira-Sousa SI, Caldeira GL, Carmo C, Laço MN, Hayden MR, Oliveira CR, Rego AC.

Mol Neurobiol. 2017 Sep;54(7):5385-5399. doi: 10.1007/s12035-016-0048-3. Epub 2016 Sep 2.


NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR.

Yoshino J, Baur JA, Imai SI.

Cell Metab. 2018 Mar 6;27(3):513-528. doi: 10.1016/j.cmet.2017.11.002. Epub 2017 Dec 14. Review.


NAD+ and sirtuins in aging and disease.

Imai S, Guarente L.

Trends Cell Biol. 2014 Aug;24(8):464-71. doi: 10.1016/j.tcb.2014.04.002. Epub 2014 Apr 29. Review.


Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

Hathorn T, Snyder-Keller A, Messer A.

Neurobiol Dis. 2011 Jan;41(1):43-50. doi: 10.1016/j.nbd.2010.08.017. Epub 2010 Aug 22.


Mitochondrial biogenesis: pharmacological approaches.

Valero T.

Curr Pharm Des. 2014;20(35):5507-9.


Comparison of Sirtuin 3 Levels in ALS and Huntington's Disease-Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models.

Buck E, Bayer H, Lindenberg KS, Hanselmann J, Pasquarelli N, Ludolph AC, Weydt P, Witting A.

Front Mol Neurosci. 2017 May 26;10:156. doi: 10.3389/fnmol.2017.00156. eCollection 2017.


Sirtuin deacetylases in neurodegenerative diseases of aging.

Herskovits AZ, Guarente L.

Cell Res. 2013 Jun;23(6):746-58. doi: 10.1038/cr.2013.70. Epub 2013 May 21. Review.


NAD(+) metabolism: Bioenergetics, signaling and manipulation for therapy.

Yang Y, Sauve AA.

Biochim Biophys Acta. 2016 Dec;1864(12):1787-1800. doi: 10.1016/j.bbapap.2016.06.014. Epub 2016 Jun 29. Review.


Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes.

Yang SJ, Choi JM, Kim L, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Park CY.

J Nutr Biochem. 2014 Jan;25(1):66-72. doi: 10.1016/j.jnutbio.2013.09.004. Epub 2013 Oct 10.


Nicotinamide adenine dinucleotide homeostasis and signalling in heart disease: Pathophysiological implications and therapeutic potential.

Mericskay M.

Arch Cardiovasc Dis. 2016 Mar;109(3):207-15. doi: 10.1016/j.acvd.2015.10.004. Epub 2015 Dec 18. Review.


Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes.

Braidy N, Berg J, Clement J, Khorshidi F, Poljak A, Jayasena T, Grant R, Sachdev P.

Antioxid Redox Signal. 2018 May 11. doi: 10.1089/ars.2017.7269. [Epub ahead of print]


Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease.

Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF.

Exp Neurol. 2010 Sep;225(1):74-84. doi: 10.1016/j.expneurol.2010.05.006. Epub 2010 Jun 1.


Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection.

Chi Y, Sauve AA.

Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):657-61. doi: 10.1097/MCO.0b013e32836510c0. Review.


Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Jin J, Albertz J, Guo Z, Peng Q, Rudow G, Troncoso JC, Ross CA, Duan W.

J Neurochem. 2013 May;125(3):410-9. doi: 10.1111/jnc.12190. Epub 2013 Mar 5.


PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond.

Tsunemi T, La Spada AR.

Prog Neurobiol. 2012 May;97(2):142-51. doi: 10.1016/j.pneurobio.2011.10.004. Epub 2011 Nov 9. Review.


Impaired PGC-1alpha function in muscle in Huntington's disease.

Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF.

Hum Mol Genet. 2009 Aug 15;18(16):3048-65. doi: 10.1093/hmg/ddp243. Epub 2009 May 21.

Supplemental Content

Support Center